Detalhe da pesquisa
1.
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
N Engl J Med
; 388(8): 706-718, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36812434
2.
How I treat von Willebrand disorders in older adults.
Blood
; 143(3): 197-204, 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37672774
3.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Blood
; 137(16): 2231-2242, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512413
4.
Consistency of serial ultrasonographic joint tissue measurements by the Joint tissueActivity and Damage Exam (JADE) protocol in relation to hemophilic joint health parameters.
BMC Musculoskelet Disord
; 24(1): 299, 2023 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37061676
5.
Blood pressure in persons with haemophilia with a focus on haemophilia-specific risk factors.
Haemophilia
; 28(6): 977-985, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35768896
6.
Diabetes, hepatitis C and human immunodeficiency virus influence hypertension risk differently in cohorts of haemophilia patients, veterans and the general population.
Haemophilia
; 28(6): e228-e236, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877992
7.
Risk of diabetes in haemophilia patients compared to clinic and non-clinic control cohorts.
Haemophilia
; 28(3): 445-452, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35238443
8.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
N Engl J Med
; 379(9): 811-822, 2018 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30157389
9.
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Blood
; 134(24): 2127-2138, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697801
10.
Quantitative measurements of haemophilic joint tissues by point-of-care musculoskeletal ultrasound: Associations with clinical and functional joint outcome parameters.
Haemophilia
; 27(5): 866-875, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34171150
11.
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
N Engl J Med
; 377(9): 809-818, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28691557
12.
Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease.
Blood Cells Mol Dis
; 80: 102369, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31677454
13.
How I treat type 2B von Willebrand disease.
Blood
; 131(12): 1292-1300, 2018 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29378695
14.
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
Pediatr Blood Cancer
; 67(10): e28474, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32776489
15.
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.
Haemophilia
; 25(2): 213-220, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30724422
16.
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).
Haemophilia
; 25(3): 382-391, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31016855
17.
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
Haemophilia
; 25(1): 33-44, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30427582
18.
Development and Reliability of the Joint Tissue Activity and Damage Examination for Quantitation of Structural Abnormalities by Musculoskeletal Ultrasound in Hemophilic Joints.
J Ultrasound Med
; 38(6): 1569-1581, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30371941
19.
Emicizumab in Hemophilia A.
N Engl J Med
; 382(8): 785, 2020 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32074440
20.
A new era for hemophilia B treatment.
Blood
; 127(14): 1734-6, 2016 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27056991